Skip to content

Advertisement

  • Research
  • Open Access

Positively increased visceral adiposity index in hyperuricemia free of metabolic syndrome

  • 1Email author,
  • 2,
  • 1,
  • 1 and
  • 1
Contributed equally
Lipids in Health and Disease201817:101

https://doi.org/10.1186/s12944-018-0761-1

  • Received: 12 December 2017
  • Accepted: 26 April 2018
  • Published:

Abstract

Background

Visceral adiposity index (VAI) was closely associated with metabolic syndrome, however almost no research focused on VAI and hyperuricemia, therefore, this study was conducted to determine the relationship of VAI and hyperuricemia free of metabolic syndrome and estimate the power of VAI as predictor for hyperuricemia.

Methods

A cross-sectional research coming from a health check-up program was conducted. All participants were divided into four groups according to VAI quartiles. A multivariate logistic analysis was used to analyze the relationship between the quartiles and hyperuricemia. A receiver operating characteristic (ROC) curve analysis was used to evaluate the accuracy of predictions for hyperuricemia.

Results

VAI was independent risk factor of hyperuricemia. The ORs of which in the upper quartile were 3.077 (95%CI 1.78-5.293), P = 0.000, in model 1, after adjusting for age, systolic blood pressure, diastolic blood pressure, heart rate, fast plasma glucose, serum creatinine, triglyceride, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol; and 3.041 (95CI 1.767-5.233), P = 0.000, in model 2, after adjusting for the above plus physical activity, diet, smoking habits, alcohol consumption, hypertension and diabetes history. The area under the ROC curve (AUC) value of VAI was 0.618 (95%CI 0.572-0.665), P = 0.000; it was higher than WC, which was 0.556 (95%CI 0.508-0.604), P = 0.024, for hyperuricemia.

Conclusions

VAI was associated with hyperuricemia among individuals free of metabolic syndrome, and also a powerful indicator.

Keywords

  • Visceral adiposity index
  • Hyperuricemia
  • Metabolic syndrome
  • Obesity

Background

There are two kinds of central obesity: subcutaneous and visceral fat mass, and waist circumference (WC) alone does not help distinguishing them [1]. The Visceral Adiposity Index (VAI), which is based on WC, body mass index (BMI), triglycerides(TG), and high density lipoprotein cholesterol (HDL-C) and was recently introduced by Amato et al. [2], was used as a marker of visceral fat dysfunction, and been suggested as an indicator of Metabolic syndrome (MetS) [3, 4]. MetS, which was defined as a distinct entity which comprises the following components: central obesity, dyslipidemia, hyperglycemia and hypertension, increase a person’s risk of cardiovascular disease [5, 6], and more and more studies revealed that hyperuricemia is a risk factor of MetS [79].

Serum uric acid is a clinically useful nutritional marker [10], and hyperuricemia has been a major health problem in the world; the prevalence of which was 9.9% in men (cutoff point = 7.0 mg/dl) and 7.0% in women (cutoff point = 6.0 mg/dl) according to a national cross-sectional survey in China [11], however the prevalence of serum urate levels > 6 mg/dl was 50.4% among men and 16.3% among women in US [12]. Asymptomatic hyperuricemia, may progress into gout which characterized as monosodium urate crystal deposition, and also was independently associated with prevalent hypertension [13]. Therefore, it has been a public health burden, especially in males.

However, there was almost no research on the relationship of VAI and hyperuricemia, and MetS may be a confounder, therefore, we initiated to do this research about VAI and hyperuricemia free of MetS in Chinses males, in order to study the relationship of VAI and hyperuricemia free of metabolic syndrome and estimate the power of VAI as predictor for hyperuricemia.

Methods

Participants

A cross-sectional research from 3 Jan, 2016 to 3 Jan, 2017 was conducted. Sample size was determined by statistician, and which was more than 288 at a given confidence level of 5%, confidence interval of 95%, and central obesity epidemiology of 24.9% in China referred from Lancet [14]. The Ethics Committee of The People’s Hospital of Zhengzhou approved the study. A total of 713 male adult participants were recruited from a self-paid health check-up program at the Health Management Centre of The People’s Hospital of Zhengzhou with individual informed consent, written or oral, according to the principles expressed in the Declaration of Helsinki. The information of their anthropometric measurements, biochemical data, medical history and medication usage were well documented; subjects with acute illness, malignancy, infection including of chronic hepatitis B and chronic hepatitis C, current users of anti-thyroid, glucocorticoids, unclear cold medicine, and non-steroid anti-inflammatory drugs, were excluded, especially MetS. Finally, 633 non-MetS male participants were included in our analysis.

Questionnaire

Anthropometric measurements, medical history and medication usage were included in questionnaires as described in detail previously [15]. Participants were asked standing erect and had relaxed the abdominal muscles before WC measurement by a flexible inch tape. Measurement was taken at the end of normal expiration. Locate the top of the hip bone (iliac crest) and take the measurement just above this bony landmark, just where one finger can fit between the iliac crest and the lowest rib. The questionnaire consisted of questions regarding age, sex, a personal history of diabetes (yes vs. no), a personal history of hypertension (yes vs. no), a personal history of cardiovascular disease (yes vs. no), diet (balanced diet vs. unbalanced diet) according to Chinese Dietary Balance Index and Diet Quality Distance recommended by the Chinese Nutrition Society, Diet Quality Distance (range 0 to 84) was calculated based on DBI-07, 0-17 were looked as balanced diet, and 17-84 were looked as unbalanced diet [16], Physical activity (> 60 min/day vs. 30–60 min/day vs. < 30 min/day vs. no), > 60 min/day was considered as active physical activity, and < 30 min/day and no were considered as inactive physical activity based on our previous publication [15], smoking habits (yes[current] vs. no), alcohol intake (yes[current] vs. no); WC, height and systolic blood pressure (SBP) and diastolic blood pressure (DBP) were each measured manually [15]. Prior to BP measurements, participants were seated quietly for 5 to 10 min in a chair with arm supported at heart level and the rotator cuff positioned 3 cm above the antecubital fossa, BP was measured using Omron (SEM 1 Model) automatic BP monitor (Omron Healthcare Co., Ltd., IL, USA) with an appropriate cuff size [17, 18]. Heart rate (HR) was also documented from the automatic BP monitor. Average BP and HR were then calculated from three measurements. BMIs were calculated using the following equation: BMI = weight (kg)/height2 (m2).

Biochemical data

Biochemical data acquiring Protocols was also described in detail in our previous publication [15]. Appointments were scheduled for blood collection. Fasting venous blood draws were performed at The People’s Hospital of Zhengzhou. All blood samples were sent to the central laboratory of The People’s Hospital of Zhengzhou. The blood samples were either disposed of within 3 h or stored at 4 °C for as long as 2 days. FPG (fasting plasma glucose, FPG) testing was performed via an electrochemical luminescence immunoassay. Serum total cholesterol (TC), HDLC, TG, and low-density lipoprotein cholesterol (LDLC) were each measured using an autoanalyzer (Toshiba, Japan). Serum creatinine (Scr) was measured using overnight fasting venous blood samples, via Jaffe’s kinetic method. Uric acid was detected by uricase-based spectrophotometry.

Evaluation criteria

VAI, a sex-specific index based on WC, BMI, TG and HDLC, was calculated as follows [2]:
$$ \mathrm{Males}:\mathrm{VAI}=\left(\frac{\mathrm{WC}}{39.68+\left(1.88\times BMI\right)}\right)\times \left(\frac{\mathrm{TG}}{1.03}\right)\times \left(\frac{1.31}{\mathrm{HDL}}\right) $$
$$ \mathrm{Females}:\mathrm{VAI}=\left(\frac{\mathrm{WC}}{36.58+\left(1.89\times \mathrm{BMI}\right)}\right)\times \left(\frac{\mathrm{TG}}{0.81}\right)\times \left(\frac{1.52}{\mathrm{HDL}}\right) $$

MetS was defined as a composition of any 3 of 5 risk factors including of central obesity, raised triglycerides, lowered high-density lipoprotein cholesterol, raised fasting glucose and raised blood pressure [5, 6]. Hyperuricemia was defined as a serum uric acid (SUA) concentration exceeding the saturation point of 6.8 mg/dL (404 μmol/L) at physiologic pH and body temperature, without symptoms from crystal deposition [19].

Statistical analysis

Acquired data were analyzed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were represented as means ± SDs, and categorical variables were represented as proportions of each group. The basic characteristics of the four VAI quartiles were examined in non-MetS males. Continuous variables were analyzed via one-way ANOVA, and categorical variables were analyzed via the Chi-square test or the Fisher’s exact test.

Logistic regression models were used to determine whether VAI is associated with hyperuricemia free of MetS males. VAI was divided into four quartiles and considered a categorical variable. Model one was adjusted for age, VAI, SBP, DBP, heart rate, FPG, sCr, TC, TG, HDLC and LDLC; model two was adjusted for the above confounders, plus physical activity, diet, smoking habits, alcohol consumption, HP and DM. The lower quartile was used as a reference category. And logistic regression was also performed in analyzing the risk factor of VAI. P values less than 0.05 were considered statistically significant.

A receiver operating characteristic (ROC) curve analysis was used to evaluate the accuracy of predictions for hyperuricemia free of MetS males. The accuracy was showed as the area under the ROC curve (AUC) with 95% confidence interval (CI). To determine the appropriate cut-off point for each adiposity index, the score with the highest Youden’s index (sensitivity+specificity-1, Youden’s Index) was considered as the optimal cut-off one.

Results

The basic characteristics of the male and female participants

As shown in Table 1, there were significant differences in inactive physical activity, diabetes mellitus, WC, BMI, DBP, HR, SUC, serum glucose, TG, HDLC, TC, and LDLC in non-MetS males, as the upper VAI quartile participants exhibited higher DBP, serum glucose, TG, TC, and LDLC, prevalence of inactive physical activity, and lower HDLC, compared with the lower VAI subjects in non-MetS males.
Table 1

Baseline characteristics of Non-metabolic syndrome health check-up population

 

VAI (male)

P

1st Quartile (n = 162)

2nd Quartile (n = 162)

3rd Quartile (n = 151)

4th Quartile (n = 158)

Age (years)

53.3 ± 16.6

54.4 ± 15.0

51.8 ± 13.8

52.7 ± 13.5

0.458

Inactive Physical Activity (%)

93(57.4%)

96(59.3%)

102(67.5%)

117(74.1%)

P < 0.05

Unbalanced Diet (%)

39(24.1%)

38(23.5%)

39(25.8%)

46(29.1%)

0.655

Current Smoking (%)

47(29.0%)

55(34.0%)

38(25.2%)

63(39.9%)

0.331

Current Alcohol (%)

25(15.4%)

21(13.0%)

22(14.6%)

26(16.5%)

0.842

Hypertension (%)

33(20.4%)

37(22.8%)

37(24.5%)

50(31.6%)

0.111

Diabetes Mellitus (%)

74(4.3%)

6(3.7%)

17(11.3%)

16(10.1%)

P < 0.05

Waist Circumference (cm)

79.7 ± 8.6

85.8 ± 8.7

90.0 ± 8.1

91.3 ± 7.9

P < 0.001

Body Mass Index (kg/m2)

21.9 ± 2.8

23.4 ± 3.0

24.6 ± 3.2

25.1 ± 2.7

P < 0.001

Systolic Blood Pressure (mmHg)

128.0 ± 20.4

129.8 ± 18.3

129.7 ± 17.0

132.3 ± 18.2

0.227

Diastolic Blood Pressure (mmHg)

76.5 ± 11.1

78.0 ± 10.2

80.6 ± 9.9

82.2 ± 9.6

P < 0.001

Heart rate (/min)

73.7 ± 11.3

72.6 ± 9.8

74.5 ± 9.6

76.8 ± 11.0

P < 0.05

Serum Creatinine (μmol/L)

85.5 ± 14.2

85.4 ± 15.3

88.7 ± 15.1

89.0 ± 16.4

0.051

Serum uric acid (mmol/L)

370.9 ± 83.0

385.4 ± 82.9

402.0 ± 83.9

431.0 ± 89.3

P < 0.001

Serum glucose (mmol/L)

4.8 ± 1.1

5.0 ± 1.2

5.2 ± 1.2

5.4 ± 1.6

P < 0.05

Triacylglycerols(mmol/L)

0.8 ± 0.2

1.1 ± 0.2

1.8 ± 0.4

3.4 ± 1.6

P < 0.001

Total Cholesterol (mmol/L)

5.1 ± 1.0

5.3 ± 0.9

5.5 ± 1.0

5.5 ± 0.9

P < 0.001

High-Density Lipoprotein Cholesterol (mmol/L)

1.7 ± 0.3

1.4 ± 0.2

1.3 ± 0.2

1.3 ± 0.3

P < 0.001

Low-Density Lipoprotein Cholesterol (mmol/L)

3.0 ± 0.8

3.4 ± 0.9

3.3 ± 0.9

3.9 ± 0.9

P < 0.01

Means ± SDs represented the continuous variables, and proportions represented the categorical variables

1st quartile of VAI: 0-0.78; 2nd quartile of VAI: 0.79-1.18; 3rd quartile of VAI: 1.19-1.90; 4th quartile of VAI: ≥1.90

Continuous variables were analyzed via One-way ANOVA, categorical variables were analyzed via the Chi-square test or Fisher’s exact test, and P value less than 0.05 was considered statistical significant

The relationship between VAI and hyperuricemia free of MetS males

As shown in Table 2, the VAI was significantly associated with hyperuricemia free of MetS males, after adjusting for age, SBP, DBP, HR, FPG, sCr, TG, TC, HDLC, and LDLC; the ORs for hyperuricemia in the upper quartile of the VAI were 3.077 (95%CI 1.78-5.293), P = 0.000, in non-MetS males. Following further adjustments for the above confounders, physical activity, diet, smoking habits, alcohol consumption, HP and DM, the ORs for hyperuricemia in the upper quartile of the VAI were 3.041 (95CI 1.767-5.233), P = 0.000, in non-MetS males.
Table 2

The relationship between visceral adiposity index and hyperuricemia free of metabolic syndrome males

VAI

Model one a

Model two b

OR (95% CI)

P

OR (95% CI)

P

1st Quartile

Reference

 

Reference

 

2nd Quartile

1.513 (0.896-2.556)

0.121

1.514 (0.896-2.557)

0.121

3rd Quartile

2.101 (1.246-3.542)

0.005

2.102 (1.247-3.543)

0.005

4th Quartile

3.077 (1.789-5.293)

0.000

3.041 (1.767-5.233)

0.000

a Adjusted for age, SBP, DBP, heart rate, FPG, sCr, triglyceride, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol; b Adjusted for the above plus physical activity, diet, smoking habits, alcohol consumption, HP and DM

Table 3 summarized the ability of three indices to predict hyperuricemia free of MetS males. The AUC value of VAI was 0.618 (95%CI 0.572-0.665), P = 0.000, and the cut-off values of which was 1.15 for hyperuricemia. The AUC value of WC was 0.556 (95%CI 0.508-0.604), P = 0.024, and the cut-off values of which was 79.5 for hyperuricemia. BMI has no significant meaning, P = 0.810.
Table 3

The power of VAI, WC and BMI in hyperuricemia free of metabolic syndrome males

 

AUC

(95% CI)

P value

Cut off

Sensitivity

1-Specificity

Yonden’s index

VAI

0.618

0.572-0.665

0.000

1.15

0.628

0.428

0.200

WC

0.556

0.508-0.604

0.024

79.5

0.781

0.655

0.126

BMI

0.494

0.445-0.543

0.810

19.05

0.939

0.901

0.038

Figure 1 compared the accuracy of VAI, WC and BMI for predicting hyperuricemia free of MetS males. Both VAI and WC were positively correlated with hyperuricemia, and VAI had the highest AUC.
Fig. 1
Fig. 1

The discriminatory power of VAI, WC and BMI in asymptomatic hyperuricemia free of metabolic syndrome males

Discussion

The study revealed that there was a significantly relationship between VAI and hyperuricemia free of MetS males. Risk of hyperuricemia was higher in the upper quartile of VAI compared to the lower quartile of VAI, the OR was 3.077 (1.789-5.293), P = 0.000. Our pilot study also performed a multivariate logistic regression using VAI values as continuous variables, which revealed that VAI was also independent risk factor of hyperuricemia free of MetS males, the OR was 2.811 (2.128-3.714), P = 0.000. VAI had the highest AUC compared with WC and BMI in hyperuricemia free of MetS males, which was not revealed in the literature to the best of our knowledge.

Some anthropometric indices of obesity had been studied to explore the relationship of which with hyperuricemia. Body shape index (BSI), body roundness index (BRI), BMI, WC and waist-to -height ratio (WHtR) were significantly associated with hyperuricemia in both males and females, and BRI rather than ABSI showed a superior predictive ability for identifying hyperuricemia than BMI in female and similar capabilities as those of WC and WHtR in the female, but not in the male gender [20]. BMI increase and hypertriglyceridemia may potentiate serum uric acid effect on gout development [21]. Another Chinese research found that WC was strongly correlated with hyperuricemia in the Asian Mongolian area [22]. One research revealed that metabolically healthy obese, which means obese individuals with a favorable metabolic profile, had a high risk for hyperuricemia among Chinese general population [23, 24]. All of these studies were not excluded of MetS, and it was still controversial which one of anthropometric indices was superior to others. However, our research reveals that VAI was superior to WC in predicting of hyperuricemia free of MetS.

VAI not only dramatically increased with SUA, but also significantly increased with DBP, and FPG, as shown in Table 1. This has been already verified in literatures. VAI was significantly increased in prehypertension and hypertension in our previous report [15]. Some studies also found that VAI was associated with diabetes [2527]. However, the underlying mechanism is puzzling. SUA was characterized as both pro-oxidant and antioxidant properties, depending on the context, and it can impair endothelial function, result to atherosclerotic risk [2830]. New founding was that Visceral fat, not subcutaneous depot, exhibited greater expression of proinflammatory, oxidative stress-related, hypoxia-induced, and proangiogenic genes; increased activated macrophage populations; and had a higher capacity for cytokine production ex vivo; thus providing clinical evidence that visceral microenvironment play key important role in atherosclerotic vascular disease [31]. Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in tumor [32], and correlated with the expression of genes related to inflammation and oxidative stress in peripheral blood cells [31]. Visceral fat adiposity was associated with sub-clinical inflammation and increased oxidative stress [33]. Therefore, the mechanism of VAI intermediated hyperuricemia was remained to be revealed.

Inactive physical activity has positively with VAI in our study. As is known dyslipidemia was the basic of VAI increase. One Mexican population study revealed that sweetened beverages intake increased the risk of hyperuricemia and obesity [34]. Maybe keep fit and diet control was helpful for visceral obesity, specially in Chinese males, since Chinese individuals had the most deleterious abdominal visceral fat distribution and accumulation other than Europeans at a given BMI or WC [35]. A prospective study should be conducted to identify their causal relationship. However, it’s time to control visceral obesity.

Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and high sensitive C-reactive protein (hs-CRP) were also measured in order to determine the relationship of indices of inflammation with VAI and hyperuricemia. Our research also revealed that IL-6, TNF-α, and hs-CRP levels are significantly increased with hyperuricemia (IL-6: r = 0.308, P < 0.05; TNF-α: r = 0.365, P < 0.05; hs-CRP: r = 0.420, P < 0.01), and also have positive correlation with VAI (IL-6: r = 0.348, P < 0.05; TNF-α: r = 0.405, P < 0.05; hs-CRP: r = 0.496, P < 0.01). It’ well known that adipocytes can synthesize TNF-α and IL-6, the synthesis of C-reactive protein (CRP) in hepatocytes is IL-6 dependent, and CRP is also associated with adipose tissue [36]. High-fat and/or calorie-rich diet may also enhance production of these proinflammatory cytokines [37]. VAI has been associated with an increase in IL-6, TNF-α, hs-CRP in obese patients [38]. TNF-α has effects on TG through adipose tissue and liver TG metabolic pathways by increasing the level of proinflammatory cytokines such as IL-6 [38, 39]. It well documented that serum uric acid was also positively associated with IL-6, TNF-α, and hs-CRP [4042]. Therefore, adiposity may be an inflammatory condition. However, the underlying mechanism is still to be revealed in the future.

Limitations

The VAI was established in Caucasian populations, its suitability for other populations needs to be further confirmed. It remains to develop a well-designed epidemiological study to determine the underling mechanism.

Conclusions

VAI was independently associated with hyperuricemia among individuals free of MetS and also a powerful indicator.

Abbreviations

AUC: 

Area under the ROC

BMI: 

Body mass index

BRI: 

Body roundness index

BSI: 

Body shape index

CI: 

Confidence interval

CRP: 

C-reactive protein

DBP: 

Diastolic blood pressure

DM: 

Diabetic mellitus

FPG: 

Fasting plasma glucose

HDL-C: 

High density lipoprotein cholesterol

HP: 

Hypertension

HR: 

Heart rate

hs-CRP: 

High sensitive C-reactive protein

IL-6: 

Interleukin-6

LDL-C: 

Low-density lipoprotein cholesterol

MetS: 

Metabolic syndrome

OR: 

Odds ratio

ROC: 

Receiver operating characteristic

SBP: 

Systolic blood pressure

Scr: 

Serum creatinine

SUA: 

Serum uric acid

TC: 

Total cholesterol

TG: 

Triglycerides

TNF-α: 

Tumor necrosis factor-alpha

VAI: 

Visceral adiposity index

VAT: 

Visceral adiposity

WC: 

Waist circumference

WHtR: 

Waist to height ratio

Declarations

Acknowledgements

We thank all of the individuals who participated in the study, and are particularly grateful to the doctors and nursed involved in this study.

Funding

This study was supported by The People’s Hospital of Zhengzhou. The funders had no role in study’s design, data collection, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets obtained and/or analyzed in the current study are available on reasonable requests from the corresponding author.

Authors’ contributions

QQ conceived the original idea for the study and undertook its design with the assistance of each of the authors. YD and DG performed research and wrote the first draft of the manuscript; YZ and SM performed research and participated in the statistical analysis. Each of the authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the ethics committee of the People’s Hospital of Zhengzhou, and written informed consent was obtained from all participants.

Consent for publication

All authors provide consent for publication of this paper.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Nephrology and Transplantation Center, The People’s Hospital of Zhengzhou, Affiliated with Southern Medical University, Zhengzhou, 450003, People’s Republic of China
(2)
Division of Cardiovascular Medicine, The People’s Hospital of Zhengzhou, Affiliated with Southern Medical University, Zhengzhou, 450003, People’s Republic of China

References

  1. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73(7):460–8.View ArticlePubMedGoogle Scholar
  2. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Qing L, Wei R, Chan L, Xiaoya Z, Xin X. Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency. J Endocrinol Investig. 2017;40(6):653–61.Google Scholar
  4. Motamed N, Khonsari MR, Rabiee B, Ajdarkosh H, Hemasi GR, Sohrabi MR, Maadi M, Zamani F. Discriminatory ability of visceral adiposity index (VAI) in diagnosis of metabolic syndrome: a population based study. Exp Clin Endocrinol. 2017;125(3):202–7.View ArticleGoogle Scholar
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.View ArticleGoogle Scholar
  6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.View ArticlePubMedGoogle Scholar
  7. Zhang Q, Lou S, Meng Z, Ren X. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. Clin Rheumatol. 2011;30(6):777–87.View ArticlePubMedGoogle Scholar
  8. Nagahama K, Inoue T, Kohagura K, Ishihara A, Kinjo K, Ohya Y. Hyperuricemia predicts future metabolic syndrome: a 4-year follow-up study of a large screened cohort in Okinawa, Japan. Hypertens Res. 2014;37(3):232–8.View ArticlePubMedGoogle Scholar
  9. Wei CY, Sun CC, Wei JC, Tai HC, Sun CA, Chung CF, Chou YC, Lin PL, Yang T. Association between hyperuricemia and metabolic syndrome: an epidemiological study of a labor force population in Taiwan. Biomed Res Int. 2015;2015:369179.PubMedPubMed CentralGoogle Scholar
  10. Beberashvili I, Sinuani I, Azar A, Shapiro G, Feldman L, Stav K, Sandbank J, Averbukh Z. Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients. Nutrition. 2015;31(1):138–47.View ArticlePubMedGoogle Scholar
  11. Liu H, Zhang XM, Wang YL, Liu BC. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol. 2014;27(6):653–8.View ArticlePubMedGoogle Scholar
  12. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41.View ArticlePubMedGoogle Scholar
  13. Krishnan E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010. J Am Heart Assoc. 2014;3(2):e000157.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Tian Y, Jiang C, Wang M, Cai R, Zhang Y, He Z, Wang H, Wu D, Wang F, Liu X, et al. BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14. Lancet Diab Endocrinol. 2016;4(6):487–97.View ArticleGoogle Scholar
  15. Ding Y, Gu D, Zhang Y, Han W, Liu H, Qu Q. Significantly increased visceral adiposity index in prehypertension. PLoS One. 2015;10(4):e0123414.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Stookey JD, Wang Y, Ge K, Lin H, Popkin BM. Measuring diet quality in China: the INFH-UNC-CH diet quality index. Eur J Clin Nutr. 2000;54(11):811–21.View ArticlePubMedGoogle Scholar
  17. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.View ArticleGoogle Scholar
  18. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Hypertension. 2005;45(1):142–61.View ArticlePubMedGoogle Scholar
  19. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3–36.View ArticlePubMedGoogle Scholar
  20. Zhang N, Chang Y, Guo X, Chen Y, Ye N, Sun Y. A body shape index and body roundness index: two new body indices for detecting association between obesity and hyperuricemia in rural area of China. Eur J Intern Med. 2016;29:32–6.View ArticlePubMedGoogle Scholar
  21. Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang SY, Chen PY, Chen HC, Chang CT, Huang WL. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res. 2013;65(1):133–40.View ArticleGoogle Scholar
  22. You L, Liu A, Wuyun G, Wu H, Wang P. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. J Atheroscler Thromb. 2014;21(4):355–65.View ArticlePubMedGoogle Scholar
  23. Chen Y, Zhang N, Sun G, Guo X, Yu S, Yang H, Zheng L, Sun Y. Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: a cross-sectional study. Obes Res Clin Pract. 2016;10(Suppl 1):S84–95.View ArticlePubMedGoogle Scholar
  24. Liu L, Lou S, Xu K, Meng Z, Zhang Q, Song K. Relationship between lifestyle choices and hyperuricemia in Chinese men and women. Clin Rheumatol. 2013;32(2):233–9.View ArticlePubMedGoogle Scholar
  25. Chen C, Xu Y, Guo ZR, Yang J, Wu M, Hu XS. The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China. Lipids Health Dis. 2014;13:108.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Du T, Sun X, Huo R, Yu X. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China health and nutrition survey 2009. Int J Obes. 2014;38(6):840–7.View ArticleGoogle Scholar
  27. Wang Y, He S, He J, Wang S, Liu K, Chen X. Predictive value of visceral adiposity index for type 2 diabetes mellitus: a 15-year prospective cohort study. Herz. 2014;40(suppl 3):277–81.Google Scholar
  28. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010;49(7):1229–38.View ArticleGoogle Scholar
  29. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131–9.View ArticlePubMedGoogle Scholar
  30. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–62.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Yamaoka M, Maeda N, Nakamura S, Kashine S, Nakagawa Y, Hiuge-Shimizu A, Okita K, Imagawa A, Matsuzawa Y, Matsubara K, et al. A pilot investigation of visceral fat adiposity and gene expression profile in peripheral blood cells. PLoS One. 2012;7(10):e47377.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Lynam-Lennon N, Connaughton R, Carr E, Mongan AM, O'Farrell NJ, Porter RK, Brennan L, Pidgeon GP, Lysaght J, Reynolds JV, et al. Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma. BMC Cancer. 2014;14:907.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Gariballa S, Kosanovic M, Yasin J, El Essa A. Oxidative damage and inflammation in obese diabetic Emirati subjects. Nutrients. 2014;6(11):4872–80.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Lopez-Molina R, Parra-Cabrera S, Lopez-Ridaura R, Gonzalez-Villalpando ME, Ferrannini E, Gonzalez-Villalpando C. Sweetened beverages intake, hyperuricemia and metabolic syndrome: the Mexico City diabetes study. Salud Publica de Mexico. 2013;55(6):557–63.View ArticlePubMedGoogle Scholar
  35. Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, Massien C, Almeras N, Despres JP. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the international study of prediction of intra-abdominal adiposity and its relationship with Cardiometabolic risk/intra-abdominal adiposity. Am J Clin Nutr. 2012;96(4):714–26.View ArticlePubMedGoogle Scholar
  36. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Investig. 2007;30(3):210–4.View ArticleGoogle Scholar
  37. Das UN. Is there a role for bioactive lipids in the pathobiology of diabetes mellitus? Front Endocrinol (Lausanne). 2017;8:182.View ArticleGoogle Scholar
  38. Stepien M, Stepien A, Wlazel RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014;13:29.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48(4):751–62.View ArticlePubMedGoogle Scholar
  40. Wasilewska A, Tenderenda E, Taranta-Janusz K, Tobolczyk J, Stypulkowska J. Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr. 2012;101(5):497–500.View ArticlePubMedGoogle Scholar
  41. Lyngdoh T, Marques-Vidal P, Paccaud F, Preisig M, Waeber G, Bochud M, Vollenweider P. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One. 2011;6(5):e19901.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Di Y, Wang J, Chen Y, Sun N, Wu L, Dai X, Shen M, Ying Q, Fu S. Elevated Interleukin 1beta and interleukin 6 levels in the serum of children with hyperuricemia. J Clin Rheumatol. 2018;24(2):65–9.View ArticlePubMedGoogle Scholar

Copyright

Advertisement